Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in: memo - Magazine of European Medical Oncology 2/2017

01.06.2017 | case report

Primary signet cell carcinoma of the prostate: a case report

verfasst von: Mustafa Sungur, Aykut Buğra Şentürk, Selahattin Çalışkan, Abdullah Gürel

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Summary

Primary signet cell carcinoma of the prostate is very rare histological variant and usually originates from the stomach, colon, and pancreas. This malignancy was first reported in 1979 and there have been case series with small numbers of patients and case reports in the literature. Signet cell carcinoma of the prostate has a poor outcome when compared to classic prostate adenocarcinoma. A case of primary signet cell carcinoma of the prostate that was treated with maximal androgen deprivation therapy with zoledronic acid is reported.
Vorheriger Artikel Brentuximab vedotin in a patient with enteropathy-associated T‑cell lymphoma of the small bowel
Literatur
1.
Kwon WA, Oh TH, Ahn SH, Lee JW, Park SC. Primary signet ring cell carcinoma of the prostate. Can Urol Assoc J. 2013;7:768–71.CrossRef
2.
Celik O, Budak S, Ekin G, Akarken I, Ilbey YO. A case with primary signet ring cell adenocarcinoma of the prostate and review of the literature. Arch Ital Urol Androl. 2014;86:148–9.CrossRefPubMed
3.
Torbenson M, Dhir R, Nangia A, et al. Prostatic carcinoma with signet ring cells; a clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature. Mod Pathol. 1998;11:552–9.PubMed
4.
Fujita K, Sugao H, Gotoh T, et al. Primary signet ring cell carcinoma of the prostate: report and review of 42 cases. Int J Urol. 2004;11:178–81.CrossRefPubMed
5.
Roldán AM, Nú-ez NF, Grande E, et al. A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab. Clin Genitourin Cancer. 2012;10:199–201.CrossRefPubMed
6.
Lilleby W, Axcrona K, Alfsen GC, et al. Diagnosis and treatment of primary signet ring cell carcinoma of the prostate. Acta Oncol. 2007;46:1195–7.CrossRefPubMed
7.
Akagashi K, Tanda H, Kato S, Ohnishi S, Nakajima H, Nanbu A, Nitta T, Koroku M. Signet-ring cell carcinoma of the prostate effectively treated with maximal androgen blockade. Int J Urol. 2003;10:456–8.CrossRefPubMed
8.
Kanematsu A, Hiura M. Primary signet ring cell adenocarcinoma of the prostate treated by radical prostatectomy after preoperative androgen deprivation. Int J Urol. 1997;4:522–3.CrossRefPubMed
Metadaten
Titel
Primary signet cell carcinoma of the prostate: a case report
verfasst von
Mustafa Sungur
Aykut Buğra Şentürk
Selahattin Çalışkan
Abdullah Gürel
Publikationsdatum
01.06.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0327-3

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe

short review

Short review San Antonio 2016

short review

ASCO 2016 – update colorectal liver metastases

short review

Is there progress in the treatment of high-risk myeloma?

short review

American Society of Hematology 2016 annual meeting

short review

ASH Meeting 2016: developments in hemostaseology

review

American Society of Hematology 2016 annual meeting